Search research articles
Contact Us
Filters
Showing results (381-390 of 392) with videos related to
Page
of 40
Sort By:
European Journal of Nuclear Medicine
|
August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
G A Wiseman, C A White, M Stabin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
Malik E Juweid, Gregory A Wiseman, Julie M Vose, et al.
Cancer Immunity
|
August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
Ian D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
British Journal of Haematology
|
May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma
Narendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Leukemia & Lymphoma
|
November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
American Journal of Hematology
|
June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
Angela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
February 17, 2009
Metastatic malignant melanoma
S N Markovic, L A Erickson, T J Flotte, et al.
American Journal of Hematology
|
April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
Thomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Page
of 40
Search research articles
Search
Showing results (381-390 of 392) with videos related to
Sort By:
Page
of 40
European Journal of Nuclear Medicine
|
August 22, 2000
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
G A Wiseman, C A White, M Stabin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
Malik E Juweid, Gregory A Wiseman, Julie M Vose, et al.
Cancer Immunity
|
August 21, 2007
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma
Ian D Davis, Gregory A Wiseman, Fook-Thean Lee, et al.
British Journal of Haematology
|
May 4, 2017
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma
Narendranath Epperla, Anthony Q Pham, Brian L Burnette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2007
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
Malik E Juweid, Sigrid Stroobants, Otto S Hoekstra, et al.
Leukemia & Lymphoma
|
November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)
Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
American Journal of Hematology
|
June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
Angela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
February 17, 2009
Metastatic malignant melanoma
S N Markovic, L A Erickson, T J Flotte, et al.
American Journal of Hematology
|
April 27, 2013
A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma
Thomas E Witzig, Gregory A Wiseman, Matthew J Maurer, et al.
Leukemia
|
November 5, 2004
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma
A Dispenzieri, G A Wiseman, M Q Lacy, et al.
Page
of 40